Phase 2 Risk Clinical Trials
85 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 85 trials
Recruiting
Phase 2
Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities
HPV InfectionASC-USUterine Cervical Dysplasia+3 more
Amplexd Therapeutics, Inc.45 enrolled1 locationNCT07572396
Recruiting
Phase 2Phase 3
A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients
High Risk Neuroblastoma
Renaissance Pharma Ltd.144 enrolled2 locationsNCT07549321
Recruiting
Phase 2
Parenting in 2 Worlds Multisite Trial
Substance UseParentingMental Health Wellness 1+1 more
Arizona State University1,440 enrolled4 locationsNCT06324318
Recruiting
Phase 1Phase 2
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Acute Lymphoblastic LeukaemiaHigher Risk Myelodysplastic SyndromesAcute Myeloid Leukaemia
AstraZeneca84 enrolled30 locationsNCT07155226
Recruiting
Phase 1Phase 2
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRefractory Myelodysplastic Syndrome+4 more
M.D. Anderson Cancer Center52 enrolled1 locationNCT04128748
Recruiting
Phase 2
Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease
High-Risk Oral Precancerous Disease
Glenn J. Hanna25 enrolled2 locationsNCT06623110
Recruiting
Phase 1Phase 2
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
LeukemiaInborn Errors of MetabolismHLH+11 more
Children's Hospital of Philadelphia100 enrolled1 locationNCT06839456
Recruiting
Phase 2
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
Chronic Myelomonocytic LeukemiaAdvanced Myeloproliferative NeoplasmsIDH1-mutated Higher-Risk Myelodysplastic Syndromes
M.D. Anderson Cancer Center45 enrolled1 locationNCT06597734
Recruiting
Phase 2
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
Urothelial CarcinomaBladder CancerNon-Muscle-Invasive Bladder Cancer (NMIBC)+8 more
Michael A. O'Donnell174 enrolled1 locationNCT07322263
Recruiting
Phase 1Phase 2
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
ParagangliomaPheochromocytomaSolid Tumor Cancer+17 more
Fundación de investigación HM25 enrolled1 locationNCT06607692
Recruiting
Phase 2
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
High-risk Non-muscle Invasive Bladder Cancer
CG Oncology, Inc.325 enrolled65 locationsNCT06567743
Recruiting
Phase 1Phase 2
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Peripheral T Cell LymphomaT-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic Leukemia+4 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 1Phase 2
A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis
Clinical High Risk for Psychosis (CHR)
Monument Therapeutics Limited150 enrolled15 locationsNCT07226895
Recruiting
Phase 2
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
NeuroblastomaHigh Risk NeuroblastomaMetastatic Neuroblastoma
Memorial Sloan Kettering Cancer Center94 enrolled7 locationsNCT06057948
Recruiting
Phase 2
Resistance Training and Rapamycin to Enhance Bone Formation in Postmenopausal Women
HealthyOsteoporosis RiskOsteopenia
Odense University Hospital148 enrolled2 locationsNCT07191353
Recruiting
Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Pregnancy ComplicationsHigh Risk PregnancyAntiphospholipid Syndrome in Pregnancy+1 more
David Ware Branch55 enrolled3 locationsNCT03152058
Recruiting
Phase 1Phase 2
Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
High Risk NeuroblastomaRefractory NeuroblastomaRelapsed Neuroblastoma+1 more
Beijing Biotech36 enrolled1 locationNCT07502287
Recruiting
Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
High Risk Myelodysplastic SyndromeMyelodysplastic Syndrome With Excess Blastsde Novo Myelodysplastic Syndrome+7 more
M.D. Anderson Cancer Center270 enrolled1 locationNCT00801489
Recruiting
Phase 2
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
High-risk Prostate Cancer
VA Office of Research and Development30 enrolled6 locationsNCT05593497
Recruiting
Phase 2
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
Prostate CancerHigh-risk Prostate Cancer
Icahn School of Medicine at Mount Sinai40 enrolled1 locationNCT07027124